Hacker News Board Hacker News, browsed like a classic message board
Live data from Hacker News

Antiviral Molnupiravir Reduces Risk of Hospitalization/Death by ~50 Percent

merck.com

Post reply on HN
Print view View original

131–140 of 294 posts

Re: Antiviral Molnupiravir Reduces Risk of Hospitalization/Death by ~50 Percent

#131

Post by hunterb123 »

crooked-v wrote: post #113
hunterb123 wrote: post #94

Earlier quoted context omitted.

Maybe they couldn't get a doctor to prescribe them the human pill because of all the politicization so they took the "horse paste" version. You seem to have first hand knowledge of all these people's situations, are you following people to the livestock supply stores or talking out of your ass from stories you read on Reddit? Most people that I know have that have took Ivermectin were taking the human pill. Only on t…

It's been well-documented in the news, including people being hospitalized after overdosing on the stuff: https://www.mississippifreepress.org/15002/person-hospitaliz... https://www.usatoday.com/story/news/health/2021/08/25/iverme... https://www.fda.gov/consumers/consumer-updates/why-you-shoul...

At least one of those was debunked, but yeah the same news that said that someone was convinced to drink fish bowl cleaner because T recommended hydroxychloroquine when it turned out she was trying to poison her husband. It's a smear campaign and if people are taking it, it's because they can't get the human form. It's perfectly safe to take the human form and people take it preventively.

You'd think the HN crowd would be for elective controlled drug consumption and against pushing people into black/grey markets.

Kinda rich coming from the people who try to use ketamine (omg horse tranqs!) for everything.

Re: Antiviral Molnupiravir Reduces Risk of Hospitalization/Death by ~50 Percent

#132

Post by sjg007 »

photochemsyn wrote: post #55

Some interesting points on the nature of our pharmaceutical patent system... (and while the cohort in this study does seem a bit small, the conclusions appear to be fairly valid): > "Molnupiravir was invented at Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University, and is being developed by Merck & Co., Inc. in collaboration with Ridgeback Biotherapeutics." >…

You can thank Bob Dole for that wrt patents from Federal research funds.

Re: Antiviral Molnupiravir Reduces Risk of Hospitalization/Death by ~50 Percent

#133

Post by mhb »

rich_sasha wrote: post #117
photochemsyn wrote: post #55

Some interesting points on the nature of our pharmaceutical patent system... (and while the cohort in this study does seem a bit small, the conclusions appear to be fairly valid): > "Molnupiravir was invented at Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University, and is being developed by Merck & Co., Inc. in collaboration with Ridgeback Biotherapeutics." >…

> Clearly, this patent should be assigned to the federal government, not to Merck How about a proportional slice? That would seem fair. IP and products can have fractional ownership.

What does "fair" have to do with anything? Are you suggesting that your proposal maximizes the amount of health-improving interventions that society will receive in the future? Do you have any reason to conclude that what you're suggesting will be even a slight improvement?

Re: Antiviral Molnupiravir Reduces Risk of Hospitalization/Death by ~50 Percent

#134

Post by spear »

vixen99 wrote: post #118
whateveracct wrote: post #81

Earlier quoted context omitted.

Pfizer isn't emergency use

No, that is incorrect. The FDA Only renewed emergency use authorization for Pfizer; Approval was for BioNTech’s Comirnaty with additional safety studies required (until 2027). It's currently not available in the US.

It's the same thing -- Comirnaty is the brand name of the Pfizer/BioNTech COVID vaccine.

Re: Antiviral Molnupiravir Reduces Risk of Hospitalization/Death by ~50 Percent

#135

Post by loeg »

mhb wrote: post #133
rich_sasha wrote: post #117

Earlier quoted context omitted.

> Clearly, this patent should be assigned to the federal government, not to Merck How about a proportional slice? That would seem fair. IP and products can have fractional ownership.

What does "fair" have to do with anything? Are you suggesting that your proposal maximizes the amount of health-improving interventions that society will receive in the future? Do you have any reason to conclude that what you're suggesting will be even a slight improvement?

As a taxpayer / healthcare consumer who is not employed in pharma -- yeah, it would be nice if we (the US) did a little less subsidizing of drug development for the rest of the world. Proportional ownership of sponsored drugs seems like a nicely aligned incentive. What am I missing?

Re: Antiviral Molnupiravir Reduces Risk of Hospitalization/Death by ~50 Percent

#136

Post by hncurious »

endisneigh wrote: post #3

Hospitalization from COVID-19

There's a joke in here about the conflation of the data all throughout the pandemic and how there's been a failure to differentiate between with Covid and from Covid.

https://www.theatlantic.com/health/archive/2021/09/covid-hos...

Re: Antiviral Molnupiravir Reduces Risk of Hospitalization/Death by ~50 Percent

#138

Post by dham »

divbzero wrote: post #74
lsternlicht wrote: post #43

Phase 3 trial was stopped on a positive interim analysis by DSMB and in consultation with FDA Interim analysis was performed on approximately half of the total enrolled patients (775 of the 1550). Trial included many delta and other variant patients ————— Efficacy • ~50% reduction in hospitalization (14.1% PBO vs 7.3% drug) • 100% reduction in deaths (8 PBO vs 0 drug) ————— Safety • fewer adverse reactions in the dru…

Looks like the clinical trial was for age 18 and above so an EUA probably would not allow use in children.

I mean I think that's ok at this point. Kids are at greater risk of a lot of other things before Covid. We're going to have to figure out how to get our kids to become nose breathers again and fix their enlarged adenoids.

Re: Antiviral Molnupiravir Reduces Risk of Hospitalization/Death by ~50 Percent

#139

Post by programmarchy »

ceejayoz wrote: post #124
dukeofdoom wrote: post #96

Earlier quoted context omitted.

Last time I kept up with this, it was some purposeful legal loophole. The drug that got approved, is not yet available. I have a friend who is a nurse that's getting fired because she will not take the vaccine. She has patients that had adverse effects from the vaccine. I totally understand why she would not take it.

> Last time I kept up with this, it was some purposeful legal loophole. The drug that got approved, is not yet available. No, that was a maliciously stupid misreading of the FDA's statement. https://www.reuters.com/article/factcheck-fda-pfizer/fact-ch... > The FDA state that Comirnaty has the same formulation as the EUA-approved (Emergency Use Authorization) Pfizer vaccine and is interchangeable (here). Their website…

The language still seems slippery because while the formulation may be the same and interchangeable for providers, the legal process bound to the license could be different for the recipient. If the PREP Act still applies, then there’s less recourse for anyone that may experience an adverse reaction.

Re: Antiviral Molnupiravir Reduces Risk of Hospitalization/Death by ~50 Percent

#140

Post by rflec028 »

Ivermectin is inexpensive to manufacture, is extremely safe, and is currently being used by many countries to both treat and prevent the spread of covid.

Molnupiravir had concerns during its development of the drug having mutagagenic properties.

Why not just use the inexpensive, safe, proven effective medication?

Post reply on HN